Form 4: Alnylam Pharmaceuticals CEO Yvonne Greenstreet Reports Stock and Option Transactions

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Summary

• On March 1, 2024, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, reported transactions involving the company's stock.
• She acquired 23,754 restricted stock units (RSUs) and disposed of an unspecified amount of common stock.
• Greenstreet also acquired 46,394 stock options with an exercise price of $152.61.
• Following these transactions, she beneficially owns 71,882 shares of common stock directly and 407 shares indirectly through a managed account.
• The RSUs vest over a three-year period, and the stock options vest over a four-year period, contingent upon her continued service with Alnylam.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and expected, with no clear indication of positive or negative implications for the company's outlook.

Positives

• The acquisition of RSUs and stock options suggests confidence in Alnylam's future performance.
• The vesting schedules for the RSUs and stock options incentivize long-term commitment from the CEO.

Negatives

• The disposition of common stock could be interpreted negatively, although the quantity is not specified.

Risks

• The value of the RSUs and stock options is contingent upon Alnylam's stock price performance.
• The vesting of the RSUs and stock options is dependent on Greenstreet's continued employment with the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the granting of RSUs and stock options implies an expectation of future growth and value creation at Alnylam.

Industry Context

Insider transactions are closely watched in the pharmaceutical industry as indicators of management's confidence in the company's prospects, especially given the long development timelines and regulatory hurdles involved in bringing new drugs to market.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, often used to align management's interests with those of shareholders.
• Vesting schedules of three to four years are typical for RSUs and stock options in similar companies.
• Comparing the size of the RSU and option grants to those of CEOs at comparable biotech firms (e.g., Ionis Pharmaceuticals, Sarepta Therapeutics) would provide further context.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.
• Employees may view the executive compensation as a sign of the company's commitment to its leadership.

Key Dates